Serina Therapeutics, Inc. (SER) Stock Price & Analysis
Serina Therapeutics, Inc. (SER) rose 2.55% to USD 2.57 as of September 9, 2026 at 15:26 UTC, according to Nexqual real-time market data.
SER last closed at USD 2.57; the session ranged USD 2.35–2.78 on volume of 299,338 shares. Market capitalization is —, with a 52-week range of USD 1.22–5.83 (ASE). Source: Nexqual, September 9, 2026 at 15:26 UTC.
Key Statistics (as of September 9, 2026 at 15:26 UTC)
| Price | USD 2.57 |
|---|---|
| Change | ▲ 2.55% (up) |
| Previous Close | USD 2.57 |
| Open | USD 2.57 |
| Day Range | USD 2.35 – 2.78 |
| 52-Week Range | USD 1.22 – 5.83 |
| Volume | 299,338 shares |
| Market Cap | — |
| Exchange | ASE |
Technical Analysis (SER)
Nexqual's technical model rates SER "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of September 9, 2026 at 15:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.53 (neutral) |
| vs SMA50 | Above (USD 2.34) |
| MACD | 0.06 (positive) |
From Serina Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies.
- In addition, the FDA may require testing, including Phase 4 trials, and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.
- In February 2026, we enrolled and dosed our first patient in our Phase 1b clinical trial for SER-252. 6 Table of Contents Our Strategy Our strategy is to develop and commercialize polymer therapeutics based on conjugation of suitable small molecules to our proprietary POZ.
- We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
Partnerships
- In October 2023, Serina entered into a non-exclusive license agreement with Pfizer to use our POZ polymer technology for use in lipid nanoparticle drug delivery formulations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AZI | Autozi Internet Technology (Glo | USD 1.25 | ▲ 0.81% |
| LNAI | Lunai Bioworks Inc. | USD 2.55 | ▲ 6.69% |
| TURB | Turbo Energy, S.A. | USD 1.24 | ▲ 1.64% |
| NAMM | Namib Minerals | USD 1.32 | ▼ 1.49% |
| LIMN | Liminatus Pharma, Inc. | USD 3.53 | ▼ 4.85% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 15:26 UTC. This page is informational and not investment advice.